In January through September 2010, Ropharma reported net profit of RON12.1 million.
Ropharma said total revenue rose 7% on the year to roughly RON245 million in the first nine months, while overall costs increased 9% to RON274 million. Operating expenses advanced 13% on the year, mostly due to the launch of 12 new stores, the company said in its financial report.
Total sales increased 7% to RON281.2 million in the first nine months, from RON262.5 million in the same period of 2010.
End-September, Ropharma had overall debts of RON256 million, up 24% from December last year.
According to company estimates, Romania’s retail pharmaceuticals market declined 2.92% on the year to RON6 billion in January through September.
Ropharma is indirectly owned by local businessman Mihai Miron. Cyprus-registered ADD Pharmaceuticals holds a 17.97% stake, while Rimia Investments holds 20.23%. Other shareholders include Arrow Pharmaceuticals with 31.31% and Romania’s privatization authority AVAS with 0.33%.
The company has a share capital of RON29.1 million, split into 291 million shares with a face value of RON0.1.
On the Bucharest bourse Monday, Ropharma closed up 1.3% at RON0.78 a share. (EUR1=RON4.3243)